If everything goes well, FRX's EPS may retake $3 level in 2019. But with changing marketing environment, "everything goes well" means high risks. Cariprazine is what FRX's future is relying on. However, the Seroquel generics has already hiitted the market, and once-daily Seroqual XL generics will hit the market in January 2016.
Carl Ichan owned 30.66M shares. Adding an increment of 1.2M shares will reach the 12% limit. And it is hard to understand what is Ichan's real intention.
Another bad news for Cariprazine: Abilify (aripiprazole) will be genericized in April 2015. Note that Seroquel (quetiapine) already hitted the merket. Both Seroquel and Abilify are highly effective and safe. It is hard for Cariprazine to compete in such a genericized market.